

Date: 16th February, 2023

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla
Complex, Bandra (E), Mumbai – 400 051

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its Injectable Facility (F-3) at Karkhadi

Ref.: Our earlier intimation dated 1st September, 2022 - USFDA inspection at Alembic Pharmaceuticals' Injectable Facility (F-3) at Karkhadi

This is to inform the exchange that the Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our Injectable Facility (F-3) at Karkhadi from 18th August, 2022 to 30th August, 2022. This was a pre-approval inspection for ANDAs filed with the USFDA. The Company has already started receiving ANDA approvals manufactured at this facility.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123